JMP Securities initiated coverage on Summit Therapeutics Inc. (NASDAQ:SMMT), noting the company’s initial focus on infectious ...

Merck's Q3 revenue rises, led by Keytruda's strong 17% YoY growth. Gardasil demand challenges in China impact sales, with ...

Merck (MRK) is set to announce Q3 earnings on October 31st. Analysts expect a profit of $1.57 per share on revenue of $16.51B ...

Merck’s Keytruda receives European approval for two new indications in gynaecologic cancers: Rahway, New Jersey Friday, October 25, 2024, 09:00 Hrs [IST] Merck, known as MSD out ...

Keytruda is now under threat not only from ... a further potential $1.7 billion in developmental, regulatory and commercial milestone payments. Other issues that affected performance were a ...

Welcome to the Moderna third quarter 2024 conference call. [Operator instructions] Please be advised today's conference is ...

Despite challenges in GARDASIL sales, Merck & Co Inc (MRK) reports robust growth in KEYTRUDA and new product launches, ...

Shares in Merck & Co were more than 2% lower as New York trading entered its latter half on Thursday. The US pharma giant ...

Merck & Co’s attempts to move its checkpoint inhibitor Keytruda into prostate cancer have been blocked once again, continuing a run of disappointing studies with immunotherapies in the disease.

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...